Please activate JavaScript!
Please install Adobe Flash Player, click here for download

ePaper - CCN Ausgabe - Number 2013-3

5 4 3 2 1 0 0 30 60 90 120 150 180 Time in Days 2.8% 0.5%HR: 0.16 [95% CI:0.02, 1.36] Death(%) MGuard BMS/DES P=0.056 MGuard EPS continues to show a consistent trend in lower mortality rates Death at 6 Months MASTER Trial Results: MGuard Outperforms BMS & DES in STEMI Patients* MAL-038-13-01 CE Marked | Not available for sale in the USA ThE Only EMBOlIc PrOTEcTIOn STEnT DESIGnED fOr AMI MASTER* Acute Results: a Significantly Superior Complete ST-Resolution (MGuard 57.8%, Control 44.7%, p = 0.008) a Significantly Superior TIMI 3 Flow (MGuard 91.7%, Control 82.9%, p = 0.006) a Zero Mortality with MGuard at 30 days (MGuard 0%, Control 1.9%, p = 0.06) * Multicenter, Randomized Trial, 433 patients, 9 countries, 50 centers, Primary Endpoint Complete ST-Resolution, Published in JACC (Stone et. al, 2012) MASTERMASTERMASTERMASTER PRIMARy EnDPoInT AChIEvED 6-Month Update Embolic Protection Stent 1-Year results will be presented at the TCT 2013 in San Francisco

Pages